Biomarin Technologies B.V.

13 patents currently held · Updated Nov 14, 2026

7 more in force are now held by other companies

Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.

Previously recorded as Prosensa Technologies B.V. (to 2015)

Ending by 2030

Jul 2028

Next term end

When these terms end

5 yrs10 yrs20 yrs

Held patents by the year their term ends

20262027202820292030203120322033203420352036203720382039204020412042204320442045

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.

1 fee due Jul 14, 2027
The maintenance fee for Oligonucleotide comprising an inosine for treating DMD (US 10,533,171) comes due Jul 14, 2027. Unpaid by Jan 14, 2028, it lapses early.

Which patents, and when each one lapses · Pro

Recent changes

1 term has ended since Aug 16, 2026

Patents held now

Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.

Patent	Title	Status	Expires	Confidence
US 8,519,097	Molecules for targeting compounds to various selected organs or tissues In force Term ends Jul 14, 2028 · From the USPTO record	In force	Term ends Jul 14, 2028	From the USPTO record
US 9,528,109	METHODS AND MEANS FOR EFFICIENT SKIPPING OF EXON 45 IN DUCHENNE MUSCULAR DYSTROPHY PRE-mRNA In force Term ends Oct 27, 2028 · Low confidence	In force	Term ends Oct 27, 2028	Low confidence
US 9,926,557	METHODS AND MEANS FOR EFFICIENT SKIPPING OF EXON 45 IN DUCHENNE MUSCULAR DYSTROPHY PRE-mRNA In force Term ends Oct 27, 2028 · Medium confidence	In force	Term ends Oct 27, 2028	Medium confidence
US 11,427,820	METHODS AND MEANS FOR EFFICIENT SKIPPING OF EXON 45 IN DUCHENNE MUSCULAR DYSTROPHY PRE-mRNA In force Term ends Oct 27, 2028 · Medium confidence	In force	Term ends Oct 27, 2028	Medium confidence
US RE48,468	Means and methods for counteracting muscle disorders In force Term ends Oct 27, 2028 · From the USPTO record	In force	Term ends Oct 27, 2028	From the USPTO record
US 10,246,707	Method for Efficient Exon (44) Skipping in Duchenne Muscular Dystrophy and Associated Means In force Ends no later than May 14, 2029 · Low confidence	In force	Ends no later than May 14, 2029	Low confidence
US 10,533,171	Oligonucleotide comprising an inosine for treating DMD In force Term ends Apr 26, 2030 · From the USPTO record	In force	Term ends Apr 26, 2030	From the USPTO record
US 11,034,956	Oligonucleotide comprising an inosine for treating DMD In force Term ends Apr 26, 2030 · From the USPTO record	In force	Term ends Apr 26, 2030	From the USPTO record
US 11,634,714	Oligonucleotide comprising an inosine for treating DMD In force Term ends Sep 29, 2030 · From the USPTO record	In force	Term ends Sep 29, 2030	From the USPTO record
US 10,179,912	RNA Modulating Oligonucleotides with Improved Characteristics for the Treatment of Duchenne and Becker Muscular Dystrophy In force Term ends Jan 28, 2033 · Medium confidence	In force	Term ends Jan 28, 2033	Medium confidence

10 of 13 patents shown.

Pro members see all 13.

Pro members: see all 13 patents

Also on record, not counted in the 13: 7 patents in force now held by others · 5 lapsed for an unpaid fee · 1 surrendered on reissue. List them

Sources and methods

Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand. How this record was built

Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.

Export every term end as CSV · Pro

Published applications

US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.

4 pending · 9 abandoned · 6 no status recorded

List them